Surgery Partners, Inc. (NASDAQ:SGRY) Insider Harrison R. Bane Sells 56,315 Shares

Surgery Partners, Inc. (NASDAQ:SGRY) insider Harrison R. Bane sold 56,315 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the sale, the insider now directly owns 107,037 shares of the company’s stock, valued at approximately $2,744,428.68. The trade was a 34.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Surgery Partners Stock Performance

Shares of NASDAQ:SGRY opened at $25.35 on Thursday. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. Surgery Partners, Inc. has a 1-year low of $19.50 and a 1-year high of $35.29. The stock has a market capitalization of $3.22 billion, a P/E ratio of -52.81, a P/E/G ratio of 17.77 and a beta of 2.60. The business has a 50-day moving average price of $21.99 and a two-hundred day moving average price of $26.84.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The business had revenue of $770.40 million for the quarter, compared to the consensus estimate of $768.99 million. During the same period last year, the firm earned $0.15 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. Equities analysts predict that Surgery Partners, Inc. will post 0.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SGRY has been the subject of a number of recent analyst reports. Macquarie reaffirmed an “outperform” rating and set a $34.00 price target on shares of Surgery Partners in a report on Tuesday, November 19th. JPMorgan Chase & Co. lowered their target price on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a research note on Tuesday, December 3rd. Bank of America assumed coverage on Surgery Partners in a report on Monday, December 16th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Royal Bank of Canada decreased their price objective on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Surgery Partners presently has an average rating of “Moderate Buy” and an average target price of $36.56.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. KBC Group NV grew its stake in shares of Surgery Partners by 31.8% during the third quarter. KBC Group NV now owns 2,385 shares of the company’s stock worth $77,000 after purchasing an additional 576 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Surgery Partners by 747.6% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company’s stock worth $124,000 after buying an additional 3,379 shares during the period. MeadowBrook Investment Advisors LLC increased its stake in shares of Surgery Partners by 16.6% in the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company’s stock valued at $218,000 after acquiring an additional 1,460 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Surgery Partners in the 4th quarter valued at approximately $245,000. Finally, Creative Planning bought a new position in Surgery Partners during the 3rd quarter worth approximately $258,000.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.